Scientists may have uncovered the most critical symptom of COVID-19 death.
OFFICIAL statistics now reveal that the virus is killing an average of 100 people every day in the United Kingdom. While the vaccination has reduced the risk of severe infection-related consequences, scientists and academics are still looking into other options for preventing mortality.
With the reopening of schools and institutions in the coming weeks, scientists expect case rates to rise. Although data suggests that antibody levels drop in the weeks and months after the second jab, it is unknown what effect this has on vaccinations’ capacity to protect against severe disease and death. Researchers have discovered how a critical enzyme that behaves similarly to snake venom wreaks havoc on the body’s organs, increasing the risk of death. Furthermore, these discoveries could have a big impact on the development of new COVID-19 treatments.
The release of the sPLA2-IIA enzyme in COVID-19 patients may be the most important predictor of death, according to researchers.
sPLA2-IIA, which is comparable to an active enzyme found in rattlesnake venom, is found in low concentrations in healthy people and has long been thought to have a role in bacterial infection defense.
According to Floyd Chilton, principal author on the paper, when the enzyme circulates at high levels, it has the ability to destroy the body’s essential organs.
“It’s a bell-shaped curve of disease resistance vs host tolerance,” Doctor Chilton explained.
“In other words, this enzyme is attempting to eliminate the virus, but it is produced in such large quantities at some moments that things go horribly wrong, damaging the patient’s cell membranes and contributing to multiple organ failure and death.”
The study provides a new target to prevent COVID-19 death, according to study co-author Maurizio Del Poeta, a distinguished professor in the Department of Microbiology and Immunology at Stony Brook University’s Renaissance School of Medicine.
“Doctor Chilton came up with the notion of identifying potential prognostic markers in COVID-19 patients,” he stated.
“He first approached us last fall with the notion of analyzing lipids and metabolites in COVID-19 patents’ blood samples.”
Del Poeta and his colleagues gathered blood plasma samples and data from 127 hospitalized patients for the study.
The researchers also used data from a second cohort of 154 patient samples.
“Brinkwire Summary News,” says the doctor.